Golden single product, the heart and brain with treatment - Yixinone dispersible tablets

According to the World Health Organization: the number of people suffering from cardiovascular disease in China has reached 300 million, i.e. 2 out of every 10 adults suffer from cardiovascular disease. Worse still, about 3.5 million people die of cardiovascular disease every year, which is equivalent to 1 person dying of cardiovascular disease every 10 seconds.
Coronary heart disease, angina pectoris, hyperlipidemia, which we are too familiar to be familiar with, appear frequently in our lives. With its high prevalence, high disability rate and high mortality rate, it has become a serious threat to our lives and health.
When these diseases are no longer only for those we thought the middle-aged and elderly, began to appear frequently in the younger generation, many people want to know what factors lead to the high incidence of cardiovascular diseases?
It's bad habits: smoking and drinking, staying up late, irregular diet ......
It's high blood pressure: long-term high blood pressure can make the arterial blood vessel walls thicken or harden and the lumen become thin, which in turn affects the blood supply to the heart and brain.
Is diabetes: diabetes is an independent risk factor for heart disease or ischemic stroke, and with the progression of diabetes, various types of cardiovascular and cerebrovascular complications will gradually appear, such as coronary atherosclerosis, cerebral infarction, and formation of atherosclerotic plaques in the lower limbs.
It's obesity, it's aging, it's gender (male incidence is higher than female), it's genetic ......
There are many controllable and uncontrollable factors that trigger cardiovascular disease.
What about the treatment of cardiovascular disease? Are there efficacious drugs that can control the condition?
Of course there are!
In terms of medication for cardiovascular and cerebrovascular diseases, there is a clinically used efficacious drug - Yixinone dispersible tablets.
Yixinone Dispersible Tablets
(Approval number: State Drug License Z20090717)
Yixinone Dispersible Tablets is a rare Chinese medicine preparation for the treatment of cardiovascular and cerebrovascular diseases in clinical practice.
Epsilon Dispersible Tablets with Only One Ingredient 

The main ingredient of Yixinone Dispersible Tablets is Hawthorn Leaf Extract. Although there is only one ingredient, it is not inferior in terms of function and efficacy.
Hawthorn leaf extract, as its name suggests, is the extract made from the dried leaves of hawthorn. Hawthorn leaf extract contains total flavonoids which can lower blood pressure, reduce peripheral vascular resistance, dilate coronary arteries, increase coronary flow, reduce myocardial oxygen consumption, strengthen the heart, increase cardiac output, anti-myocardial ischemia, antiplatelet aggregation, improve blood rheology, eliminate oxygen free radicals, reduce cholesterol and triglyceride, and improve blood rheology.

Sterol and triglycerides, enhance the ability to withstand hypoxia and diuretic and other pharmacological effects.
In addition to the above effects, there are also involved in the body's metabolism, maintenance of the five viscera and six bowels, spleen and stomach, antibacterial and anti-inflammatory, enhance the body's immunity, beauty, fat loss, emollient acne, hair, skin blemishes, promote gonadal secretion, improve sexual function, anti-aging and prolonging the life of the good effects, so it is worth promoting the use.

Yixinone dispersible tablets specializing in the treatment of cardiovascular and cerebrovascular diseases
The main function of Yixinone Dispersible Tablets is to activate blood circulation, remove blood stasis and promote blood circulation. It is used for chest paralysis caused by blood stasis and obstruction of veins, which is characterized by chest tightness and breathlessness, tingling in the precordial region, palpitation and forgetfulness, dizziness and tinnitus; angina pectoris in coronary heart disease, hyperlipidemia, and cerebral arterial insufficiency of blood supply.
Yixinone Dispersible Tablets with 10 Pharmacological Actions 

1, hypotensive effect, significantly reduce the average arterial blood pressure and total peripheral vascular resistance;
2、Dilatation of coronary arteries, can diastole coronary blood vessels, increase coronary blood flow;
3, cardiotonic effect, effectively increase cardiac output;
4、Anti-cardiac ischemia effect disintegrates rapidly, disperses uniformly and takes effect quickly;
5、Improve blood rheology, inhibit platelet aggregation, anti-thrombosis and anti-atherosclerosis and other effects;
6, scavenging oxygen free radical effect, stronger than ginkgo biloba flavonoids and veratrol;
7, lipid-lowering effect, significantly reduce total cholesterol and triglyceride content;
8, diuretic effect, mild, slow and long-lasting;
9, Enhance the ability to tolerate hypoxia, reduce the overall oxygen consumption;
10、Toxicology research, clinical application dose of hawthorn leaf total flavonoids is safe, no toxic side effects.

Yixinone dispersible tablets is not only the treatment of patients with cardiovascular and cerebrovascular diseases, for the majority of agents is also the agent of high quality choice. Because it is in the production of few manufacturers, excellent dosage form, specifications rare, manufacturers strictly control channels, absolute control of sales, to protect the terminal retail price, profit margins, easy to operate, the key is the gold single product effect is very good, the patient's reputation is great, the market demand is high, the development of the space.

High market demand, large space for development, not to be missed in the cardiovascular and cerebrovascular treatment of pure Chinese medicine preparation formula - Yixinone!

Other Dynamics

Mitiglinide Calcium Capsules The new version of the medical insurance catalog of clinical application advantages of analysis

Early-phase insulin secretion defect is a characteristic manifestation of abnormal insulin secretion pattern in type 2 diabetes mellitus patients, and insulinotropic agents have an important role in the treatment of type 2 diabetes mellitus. Coinciding with the successful entry of the new mealtime insulinotropic agent, Miglinide calcium, into the new version of the national health insurance catalog, Diabetes International invited Prof. Mou Yiming of the General Hospital of the Chinese People's Liberation Army to explain the advantages of the application and the applicable population of Miglinide calcium, and to analyze the benefits that will be provided to the patients after its entry into the health insurance.

Explanation of pharmacological effects of Miglinide calcium in the new version of the medical insurance catalog

Defective β-cell insulin secretion is one of the central aspects of the pathogenesis of type 2 diabetes. Coinciding with the successful entry of the new mealtime insulinotropic agent, Miglinide calcium, into the new version of the National Health Insurance Catalog, Diabetes International invited Prof. Zhigang Zhao of the Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, to make a professional analysis of the advantages of the action of the new insulinotropic agent from the perspective of pharmacology.

Effective reduction of postprandial hyperglycemia preferred medication - Miglinide calcium capsule

What's worse, the probability of diabetes is increasing among people under the age of 40, as well as pregnant women, and even primary and secondary school students in China.

Golden single product, the heart and brain with treatment - Yixinone dispersible tablets

According to the World Health Organization: the number of people suffering from cardiovascular disease in China has reached 300 million, i.e. 2 out of every 10 adults suffer from cardiovascular disease.

Pioglitazone is the preferred drug for the treatment of type 2 diabetes mellitus.

Diabetes mellitus is a disorder of sugar, fat and protein metabolism caused by a defect in insulin secretion or a decrease in the sensitivity of body tissues and cells to insulin. It is characterized by high blood glucose and is often characterized by excessive urination, drinking, eating and wasting, i.e. "three more and one less".

Drug procurement "national first standard" came drug companies or face different situations

On November 15, the full text of the "4+7" Cities Drug Centralized Purchasing Document was published. With the consent of the Central Committee for Comprehensively Deepening Reform, the State organized a pilot centralized procurement of medicines, and the scope of the pilot area is Beijing, Tianjin, Shanghai, Chongqing, as well as Shenyang, Dalian, Xiamen, Guangzhou, Shenzhen, Chengdu, Xi'an, and other 11 cities (referred to as the "4 + 7 cities"). According to the procurement documents, the first batch of banded procurement catalog totaled 31 varieties, including cefuroxime tablets, escitalopram oxalate tablets, and resuvastatin calcium tablets that have been full of three enterprises through consistency evaluation.